Before 1989, when epoetin was introduced for dialysisassociated
\nanemia, the use of intravenous (IV) iron in the United
\nStates was typically avoided. Shortly thereafter, it was shown that
\nresponses to epoetin could be improved by IV iron supplementation.
\nBy 1998, IV iron had become standard of care in dialysis patients
\nreceiving epoetin,1and the use of erythropoiesis-stimulating agents
\n(ESAs) in oncology patients was in its infancy. In the ensuing decade,
\nwe have witnessed improvements in quality of life and fewer transfusions
\namong patients receiving ESAs for the anemia associated with
\ncancer and cancer chemotherapy. Some studies have shown the maximumimprovement
\nin energy, activity, and quality of life occurswhen
\nthe hemoglobin (Hb) increases from 11 to 13 g\/dL.2 In August 2007,
\nthe Committee on Medicare and Medicaid Services issued a Decision
\nMemo restricting ESA usage when patients\u2019 Hb levels are \u000110 g\/dL.
\nThese new regulations were recommended on the basis of data suggesting
\nharm with ESAs when used outside of established guidelines.
\nTo date, no study has shown a negative impact on cancer outcomes or
\nsurvival in patients when ESAs were used in accordance with previously
\nestablished American Society of Hematology, American Society
\nof Clinical Oncology, or National Comprehensive Cancer Network
\nguidelines. Recent data in the renal literature suggest that it is not the
\nHb level, but ESA exposure, that is associated with negative
\noutcomes.<\/div>\n","protected":false},"excerpt":{"rendered":"

Editorial: J Clin Oncol Fecha: 01\/04\/2008 Auerbach M. Acceso al enlace publicador Before 1989, when epoetin was introduced for dialysisassociated<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[4],"tags":[],"_links":{"self":[{"href":"https:\/\/awge.doctime.es\/index.php\/wp-json\/wp\/v2\/posts\/268"}],"collection":[{"href":"https:\/\/awge.doctime.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/awge.doctime.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/awge.doctime.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/awge.doctime.es\/index.php\/wp-json\/wp\/v2\/comments?post=268"}],"version-history":[{"count":1,"href":"https:\/\/awge.doctime.es\/index.php\/wp-json\/wp\/v2\/posts\/268\/revisions"}],"predecessor-version":[{"id":765,"href":"https:\/\/awge.doctime.es\/index.php\/wp-json\/wp\/v2\/posts\/268\/revisions\/765"}],"wp:attachment":[{"href":"https:\/\/awge.doctime.es\/index.php\/wp-json\/wp\/v2\/media?parent=268"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/awge.doctime.es\/index.php\/wp-json\/wp\/v2\/categories?post=268"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/awge.doctime.es\/index.php\/wp-json\/wp\/v2\/tags?post=268"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}